FAQ

FAQ published on November 30, 2022
It is very important to establish the goals of therapy with patients. In this activity, Dr. Kuykendall and Dr. Bose explain how to determine treatment success based on individual goals.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.
FAQ published on November 25, 2022
In this activity, Dr. Kuykendall and Dr. Bose discuss which patients are predicted to respond to a JAK inhibitor.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.
FAQ published on November 22, 2022
As more therapies become available for patients with myelofibrosis, it can be difficult to choose the best option for second-line treatment. Dr. Bose discusses what patient factors to consider.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.
FAQ published on November 18, 2022
There are various definitions in clinical trials relating to ruxolitinib failure. Dr. Mascarenhas explains how you can decide on switching to an alternative therapy or a combination strategy.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.
FAQ published on January 13, 2022
In this activity, Dr. Verstovsek explains how to manage anemia in patients with myelofibrosis.
FAQ published on January 10, 2022
Join Dr. Gerds as he discusses how the mutational profile can be utilized to inform diagnosis and prognosis of patients with suspected MPN.
FAQ published on December 22, 2021
Dr. Spivak explains how risk is assessed in polycythemia vera and how this informs treatment decisions.
FAQ published on December 22, 2020
In this activity, Dr. Rampal discusses the many options that can be considered for patients who have anemia with myelofibrosis.
FAQ published on December 16, 2020
Dr. Rampal defines resistant or refractory PV and describes the standard of care for a patient who is hydroxyurea resistant.
FAQ published on December 10, 2020
In this activity, Dr. Raajit Rampal explains what steps to take in establishing the accurate diagnosis of polycythemia vera.
Page 1 of 2
Results 1 - 10 of 20